ARTICLE | Company News

ChemGenex Pharmaceuticals, Hospira deal

December 21, 2009 8:00 AM UTC

ChemGenex granted Hospira exclusive rights to develop and commercialize omacetaxine mepesuccinate in Europe, the Middle East and parts of Africa. The natural alkaloid that targets the ribosome to inhibit synthesis of oncoproteins is under review in the U.S. and Europe to treat Gleevec-resistant chronic myelogenous leukemia (CML) in patients who have the BCR-ABL T315I mutation. ChemGenex will complete registration with EMEA. ChemGenex will receive €11.1 million ($16.3 million) up front and up to €74.1 million ($108.7 million) in milestones, plus royalties, for CML. ChemGenex is eligible for additional milestones and royalties for the compound in other indications, such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). ...